Prevalence of sarcopenia in patients with solid tumors: A meta‐analysis based on 81,814 patients
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; none of the 10 sources its claims cite is checked for support yet.
Abstract
Background: The purpose of the present meta‐analysis was to analyze the prevalence of sarcopenia on staging computed tomography (CT) in patients with different malignant solid tumors and in different oncologic settings based on a large sample. Methods: MEDLINE, Cochrane, and SCOPUS literature databases were screened for prevalence of sarcopenia in oncologic patients up to December 2021. Overall, 280 studies met the inclusion criteria. The methodological quality of the involved studies was checked according to the Quality Assessment of Diagnostic Studies instrument. The meta‐analysis was undertaken by using RevMan 5.4 software. DerSimonian and Laird random‐effects models with inverse‐variance weights were used. Results: The included 280 studies comprised 81,814 patients with different tumors. The prevalence of sarcopenia over all included studies was 35.3%. A prevalence of sarcopenia >50% was identified in esophageal cancer, urothelial cancer, cholangiocarcinoma, prostate cancer, sarcomas, and thyroid cancer. In head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, renal cell cancer, and ovarian cancer, the prevalence of sarcopenia varied between 35% and 50%. In colorectal cancer, gastric cancer, hepatocellular cancer, and breast cancer, the prevalence of low skeletal muscle mass was <35%. In curative setting, the prevalence of sarcopenia was 39.6% and in palliative setting, it was 49.2% ( P < 0.001). Conclusions: Sarcopenia is a frequent condition in oncology with a prevalence of 35.3%. The prevalence of sarcopenia is higher in palliative setting vs curative setting. The prevalence of sarcopenia is also different in different tumors.
Overview
CoChat Summary
TL;DR
This meta-analysis of 280 studies and 81,814 patients found an overall prevalence of sarcopenia/low skeletal muscle mass (LSMM) on staging CT of 35.3% in solid tumors. Prevalence varied by tumor type and was higher in palliative (49.2%) than curative (39.6%) settings (P < 0.001).
Key findings
- Overall sarcopenia/LSMM prevalence was 35.3% (95% CI 34.9–35.6) across 280 studies and 81,814 patients; prevalence ranged from 28.3% in colorectal cancer to 61.0% in prostate cancer.
- Prevalence >50% was identified in prostate cancer, esophageal cancer, urothelial cancer, cholangiocarcinoma, sarcomas, and thyroid cancer; 35%–50% in head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, renal cell cancer, and ovarian cancer; <35% in colorectal cancer, gastric cancer, hepatocellular cancer, and breast cancer.
- In curative setting (51,751 patients, 63.3% of all patients), prevalence was 39.6%; in palliative setting (7,476 patients, 9.1%), prevalence was 49.2% (P < 0.001). The Results text also reports palliative prevalence as 49.68%, and the Discussion as 49.4%.
- Sarcopenia definitions were heterogeneous: 75.9% of patients (62,070) were assessed with different cutoffs ranging from 23 to 47 cm²/m² in women and 29.1 to 63.94 cm²/m² in men; Prado cutoffs were used in 12.5%, BMI-adjusted cutoffs in 7.3%, and 41/43 cm²/m² cutoffs in 4.3%.
Methods
- Systematic review and meta-analysis; MEDLINE, Cochrane, and SCOPUS were screened up to December 2021 using PRISMA, yielding 8,279 records and 280 included studies.
- Inclusion criteria were original investigations of adult patients with malignant solid tumors, LSMM diagnosed on pretreatment CT by skeletal muscle index (SMI) at lumbar level 3, reported prevalence, study origin, and tumor setting (curative or palliative); exclusions included reviews, experimental studies, case reports, non-English articles, pediatric patients, non-CT diagnosis, and non-SMI L3 measurements.
- Meta-analysis used DerSimonian and Laird random-effects models with inverse-variance weights in RevMan 5.4; methodological quality was assessed with QUADAS-2, and publication bias was examined with a funnel plot and Egger test.
Limitations
- Stated by the paper: English-language studies only; most included studies were retrospective (192/280, 68.6%); publication bias was present (Egger test P = 0.001); only studies estimating sarcopenia on CT using SMI at L3 were included, excluding studies using sentinel muscles such as psoas or pectoral muscle.
- Stated by the paper: patient numbers were small for thyroid cancer (257) and melanoma (115), only one study each was reported for endometrial cancer and uterine cervical cancer, and the text states no eligible studies were identified for sarcomas, thymic cancer, adrenal gland cancer, and mesotheliomas—although Table 2 lists 2 sarcoma studies (n = 252).
- Evident from the text: SMI cutoffs were highly heterogeneous (75.9% of patients assessed with different cutoffs; ranges 23–47 cm²/m² in women and 29.1–63.94 cm²/m² in men), and palliative-setting prevalence is reported inconsistently as 49.2%, 49.68%, and 49.4% across the abstract, Results, and Discussion.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
0 Valid · 0 Not valid · 7 Not checked · 27 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In curative setting (51,751 patients, 63.3% of all patients), the prevalence of LSMM was 39.6%.”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > Prevalence of sarcopenia
plainn = 51,751- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 4 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, renal cell cancer, and ovarian cancer, the prevalence of sarcopenia varied between 35% and 50%.”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 4 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, for some entities like sarcomas, thymic cancer, adrenal gland cancer, and mesotheliomas no studies that met the inclusion criteria, could be identified.”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In most cases (62,070 patients, 75.9%), different cut offs were used, ranging from 23 cm 2 /m 2 to 47 cm 2 /m 2 and from 29.1 cm 2 /m 2 to 63.94 cm 2 /m 2 in female and male patients, respectively.”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > Definition of sarcopenia
plainn = 62,070- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Total 67 7476 63.3 49.2 48.1-50.4”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 4 assumptions not shown here.
8 more claims
Create a free account to see all 34 claims and every source verdict.
- It may state two separate claims as one. 8
- The quote only partly states this claim. 2
- Probably not a substantial claim. 13
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“In fact, our analysis shows that in curative setting sarcopenia occurs in 39.4%.”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“Total 195 51,751 62.7 39.6 39.2-40.0”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“The present analysis shows that the prevalence ranges from 27.2% to 61.0%.”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“Colorectal cancer 47 33,221 60.6 28 (3) 27.8-28.7”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“In palliative setting, it is significantly higher, namely 49.4%.”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“Total 67 7476 63.3 49.2 48.1-50.4”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > Prevalence of sarcopenia
“The highest prevalence was observed in cholangiocarcinoma (55.6), prostate cancer (51.9%), esophageal cancer (50.2%), and urothelial cancer (50.0%).”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“Sarcoma 1 163 64.0 62.0 54.5-69.4”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > Prevalence of sarcopenia
“The highest prevalence was identified in prostate cancer (76.1%), renal cell cancer (55.0%), lung cancer (51.5%), and colorectal cancer (53.0%) (Table 4).”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“Esophageal cancer 2 326 66.3 74.2 69.5-79.0”
3 more findings
Create a free account to see every finding of this check.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., & Moher, D. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.02.003 · Cited by 3,490
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Martin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J., Murphy, R., Ghosh, S., Sawyer, M. B., & Baracos, V. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2722 · Cited by 2,680
Meta-DiSc: a software for meta-analysis of test accuracy data
Zamora, J., Abraira, V., Muriel, A., Khan, K., & Coomarasamy, A. (2006) · BMC Medical Research Methodology · doi:10.1186/1471-2288-6-31 · Cited by 1,883
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Simonsen, C., de Heer, P., Bjerre, E. D., Suetta, C., Hojman, P., Pedersen, B. K., Svendsen, L. B., & Christensen, J. F. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002679 · Cited by 375
Cited by
Sayer, A. A., Cooper, R., Arai, H., Cawthon, P. M., Ntsama Essomba, M.-J., Fielding, R. A., Grounds, M. D., Witham, M. D., & Cruz-Jentoft, A. J. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00550-w · Cited by 380
Sarcopenia and malignancies: epidemiology, clinical classification and implications
Zhang, F., Wu, H.-F., Shi, H., Yu, Z., & Zhuang, C.-L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102057 · Cited by 117
Impact of sarcopenia on the prognosis and treatment of lung cancer: an umbrella review
Lin, T.-Y., Chen, Y., Wu, W., Han, D., Tsai, I., Chang, K. C., & Özçakar, L. (2022) · Discover Oncology · doi:10.1007/s12672-022-00576-0 · Cited by 70
Jacob, L., Gyasi, R. M., Oh, H. Y., Smith, L., Kostev, K., Sánchez, G. F. L., Rahmati, M., Haro, J. M., Tully, M. A., Shin, J. I., et al. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13215 · Cited by 55
Correlation between sarcopenia and esophageal cancer: a narrative review
Li, S., Xie, K., Xiao, X., Xu, P., Tang, M., & Li, D. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03304-w · Cited by 48
The Importance of Nutrition in Cancer Care: A Narrative Review
Soares, C. H., Beuren, A. G., Friedrich, H. J., Gabrielli, C. P., Stefani, G. P., & Steemburgo, T. (2024) · Current Nutrition Reports · doi:10.1007/s13668-024-00578-0 · Cited by 38
Whaikid, P., & Piaseu, N. (2023) · International Journal of Nursing Sciences · doi:10.1016/j.ijnss.2023.11.002 · Cited by 38
Comp2Comp: Open-Source Body Composition Assessment on Computed TomographyPreprint
Blankemeier, L., Desai, A., Chaves, J. M. Z., Wentland, A. L., Yao, S., Reis, E. P., Jensen, M., Bahl, B., Arora, K., Patel, B. N., et al. (2023) · arXiv (Cornell University) · doi:10.48550/arxiv.2302.06568 · Cited by 36
Doxorubicin causes cachexia, sarcopenia, and frailty characteristics in mice
Cella, P. S., de Matos, R. L. N., Marinello, P. C., da Costa, J. C., Moura, F. A., Bracarense, A. P. F. R. L., Chimin, P., & Deminice, R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301379 · Cited by 35
Upper Tract Urothelial Carcinoma (UTUC) Diagnosis and Risk Stratification: A Comprehensive Review
Bitaraf, M., Yazdi, M. G., & Amini, E. (2023) · Cancers · doi:10.3390/cancers15204987 · Cited by 32
Kovač, M. B., Pavlin, T., Čavka, L., Ribnikar, D., Spazzapan, S., Templeton, A. J., & Šeruga, B. (2023) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2023.101594 · Cited by 27
Surov, A., Thormann, M., Wienke, A., Ricke, J., & Seidensticker, M. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06190-1 · Cited by 26
Self-citationRamos‐Bossini, A. J. L., Martínez, A. G., Gómez, D. L., Valverde‐López, F., Melguizo, C., & Prados, J. C. (2024) · Cancers · doi:10.3390/cancers16193356 · Cited by 26
Damm, M., Efremov, L., Jalal, M., Nadeem, N., Dober, J., Michl, P., Wohlgemuth, W. A., Wadsley, J., Hopper, A. D., Krug, S., et al. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12489 · Cited by 22
Delrieu, L., Blanc, D., Bouhamama, A., Reyal, F., Pilleul, F., Racine, V., Hamy, A., Crochet, H., Marchal, T., & Heudel, P. (2024) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2023.1292676 · Cited by 22
Hofmann, F. O., Heiliger, C., Tschaidse, T., Jarmusch, S., Auhage, L. A., Aghamaliyev, U., Gesenhues, A. B., Schiergens, T. S., Nieß, H., Ilmer, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-96238-6 · Cited by 21
Yang, D., Su, L., Zhang, L., Zhang, Y., Li, Y., Huang, T., & Huang, X. Q. (2024) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-024-08577-1 · Cited by 18
Cava, E., & Lombardo, M. (2024) · European Journal of Clinical Nutrition · doi:10.1038/s41430-024-01513-w · Cited by 18
Quagliariello, V., Berretta, M., Bisceglia, I., Giacobbe, I., Iovine, M., Giordano, V., Arianna, R., Barbato, M., Izzo, F., Maurea, C., et al. (2024) · Cancers · doi:10.3390/cancers16081487 · Cited by 18
Ciesielka, J., Jakimów, K., Majewska, K., Mrowiec, S., & Jabłońska, B. (2024) · Nutrients · doi:10.3390/nu16203569 · Cited by 18
Sarcopenia in patients with metastatic breast cancer: A systematic review and meta-analysis
Jang, M. K., Park, S., Park, C. G., Raszewski, R., Park, S., & Kim, S. (2025) · The Breast · doi:10.1016/j.breast.2025.104508 · Cited by 17
Tumor metabolism as a factor affecting diversity in cancer cachexia
Bathe, O. F. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00677.2024 · Cited by 17
Li, X., Huang, X., Lei, L., & Tong, S. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1233973 · Cited by 16
Schmeusser, B. N., Ali, A. A., Fintelmann, F. J., Garcia, J. M., Williams, G. R., Master, V. A., & Psutka, S. P. (2023) · Current Urology Reports · doi:10.1007/s11934-023-01157-6 · Cited by 14
Cao, Y., Heng, Y., Song, M., Nie, T., Liu, Z., Xu, J., Wu, X., Qin, L., Liu, T., Wu, F., et al. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.08.007 · Cited by 13
Hepatocellular carcinoma and sarcopenia: a narrative review
Revoredo, S., & Fabbro, E. D. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-23-332 · Cited by 13
Use of 3D-CT-derived psoas major muscle volume in defining sarcopenia in colorectal cancer
Takahashi, M., Sakamoto, K., Kogure, Y., Nojiri, S., Tsuchiya, Y., Honjo, K., Kawai, M., Ishiyama, S., Sugimoto, K., Nagakari, K., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12524-y · Cited by 9
Pancreatic cancer and sarcopenia: a narrative review of the current status
Tsukagoshi, M., Araki, K., & Shirabe, K. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02576-2 · Cited by 13
Update on the Assessment of GFR in Patients with Cancer
Silva, V. T. C. E., Xiong, F., Mantz, L., Sise, M. E., Herrmann, S. M., & Kitchlu, A. (2025) · Kidney360 · doi:10.34067/kid.0000000736 · Cited by 13
Terayama, M., Ohashi, M., Ri, M., Makuuchi, R., Hayami, M., Ida, S., Kumagai, K., Sano, T., & Nunobe, S. (2023) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-23-34 · Cited by 13
Delsoglio, M., Capener, R., Smith, T. R., Donald, M., Hubbard, G. P., & Stratton, R. J. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1654637 · Cited by 12
Thormann, M., Meyer, H., Wienke, A., Niehoff, J. H., Kröger, J. R., Gutzmer, R., Alter, M., Borggrefe, J., & Surov, A. (2024) · Nutrition and Cancer · doi:10.1080/01635581.2024.2401648 · Cited by 12
Self-citationGolder, A. M., Ferguson, M., McMillan, P., Mansouri, D., Horgan, P. G., Roxburgh, C. S. D., Dolan, R. D., McGovern, J., & McMillan, D. C. (2024) · Scientific Reports · doi:10.1038/s41598-024-65871-y · Cited by 12
Ultrasound for skeletal muscle assessment in surgical oncology: A scoping review
Vongchaiudomchoke, W., Cho, A.-R., Mahmoud, I., & Carli, F. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.109676 · Cited by 11
Meyer, H., Dermendzhiev, T., Hetz, M., Osterhoff, G., Kleber, C., Denecke, T., Henkelmann, J., Werdehausen, R., Hempel, G., & Struck, M. F. (2024) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13578 · Cited by 11
Time to include sarcopenia into the oncological routine
Surov, A., Wienke, A., Gutzmer, R., & Borggrefe, J. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.112939 · Cited by 11
Self-citationHisada, H., Tsuji, Y., Cho, R., Miura, Y., Mizutani, H., Ohki, D., Yakabi, S., Takahashi, Y., Sakaguchi, Y., Kakushima, N., et al. (2024) · Digestion · doi:10.1159/000536267 · Cited by 10
Wu, W., Liu, R., Wang, D., Li, Y., Yang, W., Ma, Z., Wang, L., Zhang, S., Sun, Z., Zhang, M., et al. (2025) · Nutrition · doi:10.1016/j.nut.2025.112686 · Cited by 9
Osaki, K., Fukushima, T., Suzuki, K., Kamimura, A., Yanai, S., & Morishita, S. (2024) · FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · doi:10.5387/fms.23-00019 · Cited by 9
Pickl, C., Engelmann, S. U., Girtner, F., Gužvić, M., van Rhijn, B. W. G., Hartmann, V., Holbach, S., Kälble, S., Haas, M., Rosenhammer, B., et al. (2023) · Cancers · doi:10.3390/cancers15020450 · Cited by 9
Sarcopenia in gastrointestinal cancers
Emori, T., Itonaga, M., Ashida, R., & Kitano, M. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02915-x · Cited by 8
He, S., Zhang, G., Huang, N., Chen, S., Ruan, L., Liu, X., & Zeng, Y. (2024) · Asia-Pacific Journal of Oncology Nursing · doi:10.1016/j.apjon.2024.100512 · Cited by 7
Dalmiglio, C., Brilli, L., Ciuoli, C., Maino, F., Valerio, L., Sannino, I., Cartocci, A., Guerrini, S., Zanoni, M., Marrazzo, G., et al. (2022) · Cancers · doi:10.3390/cancers14194569 · Cited by 8
Morelli, C., Formica, V., Bossi, P., Rofei, M., Guerriero, S., Riondino, S., Argirò, R., Pucci, N., Cenci, T., Savino, L., et al. (2023) · Cancers · doi:10.3390/cancers15194716 · Cited by 7
Anderson, D., Keko, M., James, J., Allaire, B., Kozono, D., Doyle, P. F., Kang, H., Caplan, S., Balboni, T. A., Spektor, A., et al. (2026) · JOR Spine · doi:10.1002/jsp2.70111 · Cited by 7
Janhunen, O., Jokelainen, O., Peltoniemi, R., Nykopp, T. K., & Arponen, O. (2024) · Acta Oncologica · doi:10.2340/1651-226x.2024.27450 · Cited by 7
He, J., Huang, Y., Huang, N., & Jiang, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1363843 · Cited by 6
Research Progress on Patients of Esophageal Cancer Complicated with Sarcopenia
Fu, P., & Xiao, X. (2024) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0281 · Cited by 6
Scott, L. M., Stefani, G. P., Soares, C. H., Crestani, M. S., & Steemburgo, T. (2024) · Nutrition and Cancer · doi:10.1080/01635581.2024.2364390 · Cited by 6
Silva, V. T. C. E., Sise, M. E., Inker, L. A., Mantz, L., Ouyang, T., Strufaldi, F. L., Gil, L. A., Caires, R. A., Coura-Filho, G. B., Sapienza, M. T., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000878 · Cited by 6
Ji, J. F., Mi, S., Hou, Z., Zhang, Z., Qiu, G., Jin, Z., & Huang, J. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03516-0 · Cited by 5
Yang, T., Liu, Z., Xiu, M., Qing, X. L., Liu, S., Xiao, W., & Lü, M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1412842 · Cited by 5
den Boer, R. B., Defize, I. L., Veldhuis, W. B., Steenhagen, E., Kerst, A., van Hillegersberg, R., de Jong, P. A., & Ruurda, J. P. H. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.107017 · Cited by 5
Smit, K. C., Derksen, J. W. G., Kurk, S. A., Moeskops, P., Koopman, M., Veldhuis, W. B., & May, A. M. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.07.001 · Cited by 4
Jia, Q., Pan, Y., Pan, D., Xia, Y., & Wu, J. (2025) · Gerontology · doi:10.1159/000546715 · Cited by 4
Zhao, Y., Ying, L., Gao, X., Tang, L., Zhang, Y., Pan, W., Tian, W., Liu, Y., & Feng, X. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1671720 · Cited by 4
Xu, Z., Luo, X., Diao, W., Tang, X., Zhang, Y., Wang, J., Jiang, Z., & Lei, T. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf369 · Cited by 4
Li, Z., Zhang, Y., Wu, H., Zhang, C., & Ye, Z. (2025) · BMC Medical Imaging · doi:10.1186/s12880-025-02087-0 · Cited by 3
Rectus Femoris Ultrasound to Evaluate Muscle During Prehabilitation for Patients With Cancer
Vongchaiudomchoke, W., Morais, J. A., Kim, D. J., Cho, A.-R., Tsang, J., & Carli, F. (2025) · Journal of Surgical Research · doi:10.1016/j.jss.2025.06.036 · Cited by 3
Pereira, L. M. B., Ruas, H. M. S., Filho, W. D. F., Alves, W. S. M., Dias, G. O., Durães, C. P., Monteiro-Júnior, R. S., Santos, S. H. S., Farias, L. C., Guimarães, A. L. S., et al. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-023-08254-9 · Cited by 3
Wang, B., Huang, Q., Xiong, Y., Huang, N., Li, J., & Zhang, S. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03808-z · Cited by 3
Deng, S., Lv, S., Liu, Y., Xu, H., Yin, H., Xiao, B., Wang, S., Lü, D., Li, Y., & Wang, X. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s492973 · Cited by 3
Cireli, E., Mertoğlu, A., Susam, S., Yanarateş, A., & Kıraklı, E. K. (2024) · Japanese Journal of Radiology · doi:10.1007/s11604-024-01692-3 · Cited by 3
Global trends in sarcopenia and cancer over the past 10 years: a bibliometric analysis
Liu, R., Wu, M., Cheng, X., Zhou, C., Cheng, C., Feng, L., & Shen, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-03185-9 · Cited by 2
Papassotiriou, I., Tentolouris, A., Ntanasis‐Stathopoulos, I., & Liontos, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1762196 · Cited by 2
Highlighting sarcopenia management in cancer treatments: evidence from umbrella meta-analysis
Yan, T., Cui, J., Chen, X., Wei, Z., Zhao, Z., Yan, B., Pan, X. T., Wang, P., & Li, X. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1831634 · Cited by 2
Sokhal, B. S., Matetić, A., Protheroe, J., Helliwell, T., Myint, P. K., Paul, T. K., Mallen, C. D., & Mamas, M. A. (2025) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70153 · Cited by 2
Nguyen, N. B., Pham, D. Q., Nguyen, M. T. N., Le, T. T. T., Anh, T. T. V., & Le, V. T. (2025) · Medicine · doi:10.1097/md.0000000000046462 · Cited by 2
Overlapping pathophysiological pathways between sarcopenia and chronic diseases
Zagami, F. (2023) · DYSONA – Life Science · doi:10.30493/dls.2022.301222 · Cited by 2
Fukushima, T., Yamasaki, M., Yamamoto, N., Arima, Y., Harino, T., Hori, S., Hashimoto, Y., Kotsuka, M., Inoue, K., Hase, K., et al. (2024) · BMJ Supportive & Palliative Care · doi:10.1136/spcare-2024-005100 · Cited by 2
Meyer, H., Wienke, A., Zamsheva, M., & Surov, A. (2022) · Urologia Internationalis · doi:10.1159/000527277 · Cited by 2
Self-citationYu, D., Chen, W., Zhang, F., Huang, H., Yu, T., Huang, G., Jiang, H., Dong, Q., Yu, Z., & Li, J. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110299 · Cited by 2
Zhao, T., Li, X.-Q., Shi, Z., Zhang, C.-B., & Zhu, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1727652 · Cited by 2
Matsuo, N., Yamaguchi, T., Yukami, H., Kodama, H., Ikegami, T., Kadono, T., Kameishi, S., Okemoto, D., Fakhrejahani, E., & Nishikawa, H. (2026) · Journal of Cancer · doi:10.7150/jca.126673 · Cited by 2
Zhang, F., Yan, Y., Li, B., Ge, C., & Wang, Y. L. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01393-8 · Cited by 1
Seely, D., Legacy, M., Conte, E., Rizzolo, E., Sweet, E. S., Chiang, P. F., Dale, L., Psihogios, A., Ennis, J., Parmar, G., et al. (2025) · CAND Journal · doi:10.54434/candj.207 · Cited by 1
Querido, N. R., Bours, M. J. L., Iersel, L. V., Beijers, A. J. M., Breukink, S. O., Janssen-Heijnen, M. L. G., Keulen, E. T. P., Konsten, J., de Vos‐Geelen, J., Weijenberg, M. P., et al. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101347 · Cited by 1
Perspective: Radiotherapy and Body Composition: Unmet Needs in Low- and Middle-Income Countries
Murphy-Alford, A. J., Grossberg, A. J., Baracos, V. E., Barbar, M., Bauer, J., Bennett, J. P., Fidarova, E., Fuller, C. D., Löser, A., Moreno, A. C., et al. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100563 · Cited by 1
Novel inflammatory-related indices for screening sarcopenia: Insights from a population-based study
Tong, Y., Li, H., Cheng, Y., Wang, H., & Mao, M. (2025) · Nutrition · doi:10.1016/j.nut.2025.112976 · Cited by 1
Surov, A., Wienke, A., Gutzmer, R., & Borggrefe, J. (2023) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/a-2213-2320 · Cited by 1
Self-citationSever, N., Yunusov, E., Çağlar, E. İ., Çelebi, A., Majidova, N., Kocaaslan, E., Erel, P., Ağyol, Y., Güren, A. K., Paçacı, B., et al. (2025) · Nutrition and Cancer · doi:10.1080/01635581.2025.2496371 · Cited by 1
Liu, R., Wang, J., Liu, W., Ye, J., Li, X., Chen, C., Zhao, K., & Wang, W. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06647-5 · Cited by 1
Svendsen, L., Jensen, S. O. B., Hansen, S., Sørensen, V., Johansen, C., Suetta, C., Pappot, H., Simonsen, C., Tang, L. H., Dalton, S. O., et al. (2026) · Acta Oncologica · doi:10.2340/1651-226x.2026.45726 · Cited by 1
Yu, J. Q., Guan, Q., Chen, Y., Zhou, L., Chen, J., & Zeng, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1584706 · Cited by 1
Metabolic Diseases and Healthy Aging: Prevention and Public Health Policy Based on Risk Factors
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5639-9 · Cited by 1
Maeda, Y., Miyamoto, Y., Ohuchi, M., Ogawa, K., Mima, K., Hiyoshi, Y., & Iwatsuki, M. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.10.033 · Cited by 1
Pulmonary acinar adenocarcinoma in a captive lioness (Panthera leo)
Ribeiro, P. R., Schwertz, C. I., Echenique, J. V. Z., Piva, M. M., Henker, L. C., Panziera, W., Hohendorff, R. V., Gomes, C. W. C., Both, M. D. C., & Sonne, L. (2023) · Veterinary Research Communications · doi:10.1007/s11259-023-10286-9 · Cited by 1
McCabe, F. J., McCabe, J. P., & Murray, O. (2023) · The Spine Journal · doi:10.1016/j.spinee.2023.06.007 · Cited by 1
Lightbody, S., Ashman, P., Badrin, A., Brennan, M., Compton, S., Emblen-Jarrett, K., Evans, R., Kalsi, T., Harari, D., Maguire, J., et al. (2025) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2025.102361
Imaging of Musculoskeletal Metabolic Diseases
Gazzotti, S., Sassi, R., Guglielmi, R., Gómez, M. P. A., & Bazzocchi, A. (2025) · Medical radiology · doi:10.1007/174_2025_591
Bezerra, A. E. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2024.tde-10062024-104018
Lima, G. B. B., Lima, G. S. D. C. E., Silva, F. S. D. S., Araújo, L. F. C., Pereira, T. P., Macedo, M. M., Rosa, T. D. S., Corrêa, H. D. L., & Amorim, C. E. N. (2024) · Research Square · doi:10.21203/rs.3.rs-4608193/v1
Kehonkoostumuksen muutokset leikatuilla mahasyöpäpotilailla
Määttä, M. (2023) · Jyväskylä University Digital Archive (University of Jyväskylä)
Vongchaiudomchoke, W. (2025) · eScholarship@McGill (McGill) · doi:10.82308/26172
李, 鸿., 吴, 婉., & 付, 雯. (2025) · 医学与健康科学研究 · doi:10.65196/w8g7cj04
Assessment of Sarcopenia and its Association with Hand Grip Strength in Elderly Population
Abbas, K., Hassan, S. Z., Abid, I., Gillani, S. M., Jan, A., & Jabbar, B. (2024) · Insights-Journal of Health and Rehabilitation · doi:10.71000/ijhr62
Accuracy of surgeons for predicting radiological sarcopenia in colorectal cancer surgery
Gonçalves, A., de Barros, A. B. D., Castro, L. M., Dutra, J., Batista, T. P., Martins, A., de Mello, M. J. G., & Leão, C. D. S. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27652
Preoperative Temporal Muscle Volume as an Independent Prognostic Marker in Glioblastoma
Sarkadi, A., Egermann, H., Mueller, A., & Lackermair, S. (2025) · Cureus · doi:10.7759/cureus.98946
Risco nutricional e sarcopenia em utentes oncológicos do Hospital do Divino Espírito Santo
Alves, N. L. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Metadata
- Authors
- Surov, A., & Wienke, A.
- Affiliations
- Otto-von-Guericke-Universität Magdeburg (DE)
- Martin Luther University Halle-Wittenberg (DE)
- Corresponding author
- Surov, Alexey
- Venue
- Journal of Parenteral and Enteral Nutrition
- Publisher
- Wiley
- Published
- 2022-06-19
- Volume
- 46
- Issue
- 8
- Pages
- 1761-1768
- ISSN
- 0148-6071 (ISSN-L)
- 1941-2444
- OpenAlex
- W4281688637
- Semantic Scholar
- b005bdabf2980f275e40a0a91b785104b1b2dae0
- Cited by
- 138
- References
- 25
- Citations by year
- 2026: 40 · 2025: 38 · 2024: 36 · 2023: 21 · 2022: 3
- FWCI
- 12.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Parenteral and Enteral Nutrition (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
- Keywords
- sarcopenia, solid tumors, prevalence, computed tomography staging, skeletal muscle mass, cancer cachexia, palliative care, curative cancer treatment, esophageal cancer, prostate cancer, head and neck squamous cell carcinoma, lung cancer, colorectal cancer, breast cancer
- MeSH terms
- Humans, Male, Pancreatic Neoplasms, Tomography, X-Ray Computed, Prevalence, Databases, Factual, Muscle, Skeletal, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


